补虚祛风方联合常规疗法治疗糖尿病肾病Ⅳ期的临床观察
Clinical observation on Buxu Qufeng Decoction combined with routine therapy in treatment of Ⅳ stage diabetic kidney disease
- 上海中医药杂志 2022年56卷第8期 页码：67-70
- 作者机构：
1.上海市宝山区中西医结合医院肾内科（上海 201999）
- 作者简介：
章巧琪，女，硕士，主治医师，主要从事中西医结合肾病的临床研究工作
米秀华，主任医师，硕士研究生导师； E-mail： 79484546@qq.com
- 基金信息：上海市卫健委中医药科研项目(2020LP014)
DOI：10.16305/j.1007-1334.2022.2201013
中图分类号：
扫 描 看 全 文
章巧琪,王萍,倪家庆等.补虚祛风方联合常规疗法治疗糖尿病肾病Ⅳ期的临床观察[J].上海中医药杂志,2022,56(08):67-70.
ZHANG Qiaoqi,WANG Ping,NI Jiaqing,et al.Clinical observation on Buxu Qufeng Decoction combined with routine therapy in treatment of Ⅳ stage diabetic kidney disease[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(08):67-70.
章巧琪,王萍,倪家庆等.补虚祛风方联合常规疗法治疗糖尿病肾病Ⅳ期的临床观察[J].上海中医药杂志,2022,56(08):67-70. DOI： 10.16305/j.1007-1334.2022.2201013.
ZHANG Qiaoqi,WANG Ping,NI Jiaqing,et al.Clinical observation on Buxu Qufeng Decoction combined with routine therapy in treatment of Ⅳ stage diabetic kidney disease[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(08):67-70. DOI： 10.16305/j.1007-1334.2022.2201013.
摘要
目的,2,观察补虚祛风方联合常规疗法治疗糖尿病肾病Ⅳ期的临床疗效。,方法,2,将85例糖尿病肾病Ⅳ期患者随机分为治疗组（43例）和对照组（42例），两组均予以基础治疗，对照组加服氯沙坦，治疗组在对照组基础上加服补虚祛风方，疗程均为6个月，观察两组临床疗效，比较中医证候积分、血糖相关指标、尿白蛋白相关指标、肾功能相关指标等变化情况。,结果,2,①试验过程中治疗组脱落3例，对照组脱落2例，最终完成试验者80例。②治疗组、对照组临床总有效率分别为90.0%、47.5%；两组临床疗效比较，治疗组优于对照组（,P,<,0.05）。③治疗前后组内比较，两组中医证候积分均较治疗前下降（,P,<,0.05）；组间治疗后比较，治疗组中医证候积分差值优于对照组（,P,<,0.05）。④治疗前后组内比较，两组空腹血糖（FPG）、餐后2 h血糖（2 hPG ）及糖化血红蛋白（HbA1c）均较治疗前降低（,P,<,0.05）；组间治疗后比较，FPG、2hPG、HbA1c差异均无统计学意义（,P,>,0.05）。⑤治疗前后组内比较，治疗组尿白蛋白/肌酐（ACR）、24 h尿蛋白定量（24 hUTP）较治疗前降低（,P,<,0.05），血清白蛋白水平较治疗前升高（,P,<,0.05），对照组无明显变化（,P,>,0.05）；组间治疗后比较，治疗组ACR、24 hUTP降低比对照组明显（,P,<,0.05）。⑥治疗前后组内比较，治疗组血清肌酐、尿素氮、胱氨酸蛋白酶抑制剂C （CYC）较治疗前下降（,P,<,0.05），肾小球滤过率（eGFR）较治疗前上升（,P,<,0.05）；对照组血清肌酐、尿素氮、CYC较前升高（,P,<,0.05），eGFR较治疗前下降（,P,<,0.05）。组间治疗后比较，治疗组血清肌酐、尿素氮、CYC、eGFR改善均优于对照组（,P,<,0.05）。,结论,2,补虚祛风方联合常规疗法可以改善糖尿病肾病Ⅳ期患者的临床症状，降低尿蛋白，保护肾脏功能。
Abstract
Objective,2,To observe the clinical efficacy of ,Buxu Qufeng Decoction in the treatment of Ⅳstage diabetic kidney disease （DKD）.,Methods,2,A total of 85 patients with Ⅳstage DKD were randomly divided into the treatment group（43 cases） and the control group（42 cases）. Both groups were given basic treatment， the control group was given losartan ， while the treatment group was given Buxu Qufeng Decoction on the basic treatment of the control group. The course of treatment in both groups was 6 months. After the treatment， the clinical efficacy were observed， and the changes in TCM syndrome score， blood glucose， urinary protein， and renal function related indexes were compared.,Results,2,①During the experiment， 3 cases in the treatment group and 2 cases in the control group were shed， and 80 cases were finally completed. ②After the treatment， the total effective rate in the treatment group was 90.0% ， and the control group was 47.5% ； the clinical effect of the treatment group was significantly better than that of the control group（,P,<,0.05）. ③After the treatment， the scores of TCM syndrome were decreased in both groups， and the difference of TCM syndrome scores in the treatment group was significantly better than that in the control group（,P,<,0.05）；④After the treatment， FPG， 2 hPG and HbA1c in two groups were decreased ,（P<,0.05）， but there were no significant differences in FPG， 2hPG and HbA1c between groups（,P,>,0.05）. ⑤After treatment， ACR and 24 hUTP in the treatment group were decreased （,P,<,0.05）， serum albumin was increased （,P,<,0.05）， but there was no significant change in the control group ,（P,>,0.05）. ACR and 24 hUTP in the treatment group were significantly lower than those in the control group （,P,<,0.05）. ⑥After treatment， serum creatinine， blood urea nitrogen and CYC in the treatment group were decreased （,P,<,0.05）， while eGFR was increased （,P,<,0.05）. In the control group， serum creatinine， blood urea nitrogen and CYC were higher than before treatment （,P,<,0.05）， while eGFR was lower （,P<,0.05）. After treatment， serum creatinine， blood urea nitrogen， CYC and eGFR in the treatment group were better than those in the control group （,P<,0.05）.,Conclusion,2,Buxu,Qufeng Decoction combined with routine therapy could improve the clinical symptoms of Ⅳstage DKD patients， reduce urinary protein， and protect kidney function.
关键词
糖尿病肾病慢性肾脏病补虚祛风方中医药疗法临床试验
Keywords
diabetic kidney diseasechronic kidney diseaseBuxu Qufeng Decoctiontraditional Chinese medicine therapyclinical trial
references
袁江姿，倪兆慧. 炎症与糖尿病肾病研究的新认识［J］. 国外医学·泌尿学分册，2003， 23（5）： 532-534.
LINDENMEYER M. Current developments in renal failure in diabetic patients［J］. Praxis（Bern 1994）， 2015， 104（4）： 187-195.
冯慧，胡杰，朱晓云，等. 糖尿病肾病中医病机探析［J］. 国际中医中药杂志，2019， 41（5）： 521-523.
陈杰，郑颖，廖琳，等. 叶景华健脾益肾、祛风活血法治疗糖尿病肾病［J］. 长春中医药大学学报，2020， 36（2）： 234-236.
中华医学会糖尿病学分会微血管并发症学组. 糖尿病肾病防治专家共识（2014年版）［J］. 中华糖尿病杂志，2014， 6（11）： 792-801.
中华中医药学会肾病分会. 糖尿病肾病诊断、辨证分型及疗效评定标准（试行方案）［J］. 上海中医药杂志，2007， 41（7）： 7-8.
袁博寒，陈洪宇，郑峰. 益气养阴通络方联合祛风湿法治疗糖尿病肾病疗效观察［J］. 中国中西医结合肾病杂志，2020， 21（12）： 1051-1054.
米秀华. 叶景华平衡法思想在慢性肾脏病治疗中的应用［J］. 上海中医药杂志，2011， 45（4）： 3-5.
李绪玲. 鹿衔草的药理作用及临床应用研究进展［J］. 中国医学创新，2010， 7（12）： 185-186.
张敏，谢圣芳，胡泳，等. 积雪草在肾脏病领域的临床应用和机制探讨［J］. 中国中西医结合肾病杂志，2021， 22（4）：3 75-376.
杨帆，方敬，郭帅，等. 地龙及其提取物治疗慢性肾脏病的研究与应用［J］. 中药药理与临床，2021， 37（6）： 222-226.
李巧月，李莲慧，李大山，等. 接骨木属植物化学成分和药理作用的研究进展［J］. 中国药房，2021， 32（9）： 1118-1130.
柳慧哲，王龄鹤，闫姿安，等. 锦鸡儿化学成分及其药理作用研究进展［J］. 延边大学学报（自然科学版），2021， 47（1）： 88-94.
0
浏览量
132
下载量
0
CSCD
1
CNKI被引量
- 网络PDF下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 沪ICP备13044091号
沪公网安备 31011502015228号 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
- 总访问量：70575 今日访问量：56